These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15671538)

  • 1. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy.
    Zitzmann S; Mier W; Schad A; Kinscherf R; Askoxylakis V; Krämer S; Altmann A; Eisenhut M; Haberkorn U
    Clin Cancer Res; 2005 Jan; 11(1):139-46. PubMed ID: 15671538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of the breast cancer cell-binding peptide, p160.
    Askoxylakis V; Zitzmann S; Mier W; Graham K; Krämer S; von Wegner F; Fink RH; Schwab M; Eisenhut M; Haberkorn U
    Clin Cancer Res; 2005 Sep; 11(18):6705-12. PubMed ID: 16166451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
    Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
    Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
    Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
    Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE; Cappelletti E; Maddalena ME; Fox JS; Feng W; Chen J; Thomas R; Eaton SM; Bogdan NJ; Arunachalam T; Reubi JC; Raju N; Metcalfe EC; Lattuada L; Linder KE; Swenson RE; Tweedle MF; Nunn AD
    J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary screening and identification of a peptide that binds specifically to gastric cancers cells with high metastasis to peritoneum].
    Bai FH; Wang J; Zhao PT; Cao SS; Lei T; Li Y; Wu KC; Fan DM
    Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(10):659-63. PubMed ID: 16681920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
    Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
    Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
    de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Krenning EP; de Jong M
    J Nucl Med; 2007 Jan; 48(1):88-93. PubMed ID: 17204703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5.
    Lopes AD; Davis WL; Rosenstraus MJ; Uveges AJ; Gilman SC
    Cancer Res; 1990 Oct; 50(19):6423-9. PubMed ID: 1698122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
    El Hilali N; Rubio N; Blanco J
    Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors.
    John CS; Vilner BJ; Geyer BC; Moody T; Bowen WD
    Cancer Res; 1999 Sep; 59(18):4578-83. PubMed ID: 10493511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
    Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
    Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
    Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
    Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
    Schottelius M; Rau F; Reubi JC; Schwaiger M; Wester HJ
    Bioconjug Chem; 2005; 16(2):429-37. PubMed ID: 15769098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a met-binding peptide from a phage display library.
    Zhao P; Grabinski T; Gao C; Skinner RS; Giambernardi T; Su Y; Hudson E; Resau J; Gross M; Vande Woude GF; Hay R; Cao B
    Clin Cancer Res; 2007 Oct; 13(20):6049-55. PubMed ID: 17947467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
    Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.